Literature DB >> 8541349

Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate.

S L Arnaiz1, M Travacio, S Llesuy, A Boveris.   

Abstract

Fenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/w in the diet) during 1-3 weeks and enzyme activities, H2O2 concentration, and H2O2 production rate were determined. A maximal increase of 150% in liver/body weight ratio was observed after 3 weeks of treatment. Acyl-CoA oxidase, catalase and uricase activities were increased by 712%, 506% and 41% respectively by treatment with fenofibrate. Se- and non Se-glutathione peroxidase and Mn-superoxide dismutase activities were increased by 331%, 188% and 130% respectively in the liver of 2 weeks-treated mice. Cu-Zn superoxide dismutase activity was not affected by fenofibrate treatment. H2O2 steady-state concentration showed an increase of 89% after 2 weeks of treatment. H2O2 production rates, and the steady-state concentrations of the intermediates HO, R and ROO, calculated using experimental data, were higher in the liver of fenofibrate-treated mice than in control animals. According to our findings, the imbalance between H2O2 production and its degradation by its metabolizing enzymes during peroxisome proliferation, would result in an increased level of H2O2 steady-state concentration, with the resulting oxidative stress which may lead to the generation of oxidative damage and to the induction of liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541349     DOI: 10.1016/0925-4439(95)00084-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process.

Authors:  Madlyn Frisard; Eric Ravussin
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Aging, resting metabolic rate, and oxidative damage: results from the Louisiana Healthy Aging Study.

Authors:  Madlyn I Frisard; Amanda Broussard; Sean S Davies; L Jackson Roberts; Jennifer Rood; Lillian de Jonge; Xiaobing Fang; S Michal Jazwinski; Walter A Deutsch; Eric Ravussin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-07       Impact factor: 6.053

3.  Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

Authors:  Eric Wiel; Gilles Lebuffe; Emmanuel Robin; Gaëlle Gasan; Delphine Corseaux; Benoît Tavernier; Brigitte Jude; Régis Bordet; Benoît Vallet
Journal:  Intensive Care Med       Date:  2005-08-16       Impact factor: 17.440

4.  Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.

Authors:  Neha Sehgal; Kanhaiya Lal Kumawat; Anirban Basu; Vijayalakshmi Ravindranath
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

5.  Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.

Authors:  Sebastian Luci; Beatrice Giemsa; Gerd Hause; Holger Kluge; Klaus Eder
Journal:  BMC Pharmacol       Date:  2007-04-16

6.  Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels.

Authors:  Mario Rivera-Meza; Daniel Muñoz; Erik Jerez; María E Quintanilla; Catalina Salinas-Luypaert; Katia Fernandez; Eduardo Karahanian
Journal:  Front Behav Neurosci       Date:  2017-07-14       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.